In summary, PLSCR1 is heterogeneously expressed by these lymphomas and chemotherapeutic regimes currently used in MCL management, including anthracyclines, could induce PLSCR1 expression suggesting a potential role of this protein in mediating tumor response to anticancer therapies. This evidence concerns the gene PLSCR1 and mantle cell lymphoma.